Translational integration with immuno-oncology will likely involve combining TRK or ligand-directed strategies with checkpoint inhibitors or myeloid-targeted agents, guided by the neurotrophin-dependent immune alterations described in osteosarcoma. The gene discussed is NTRK1; the disease is osteosarcoma.